S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
Denmark says Nord Stream 1 pipelines stop leaking
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
Market Wizard Reveals: The One Ticker Retirement Plan (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
CVE:MDP

Medexus Pharmaceuticals - MDP Stock Forecast, Price & News

C$7.75
-0.40 (-4.91%)
(As of 06/16/2021)
Add
Compare
Today's Range
C$7.70
▼
C$8.14
50-Day Range
C$7.75
▼
C$7.75
52-Week Range
C$2.80
▼
C$9.75
Volume
40,981 shs
Average Volume
68,619 shs
Market Capitalization
C$148.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$5.25

Medexus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
32.3% Downside
C$5.25 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
C$11,900 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.80 out of 5 stars

See Top Rated MarketRank™ Stocks Here
MDP stock logo

About Medexus Pharmaceuticals (CVE:MDP) Stock

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company's primary products are Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with Hemophilia B; and Rupall, which is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis, and chronic spontaneous urticaria in patients 2 years of age and older. Its products portfolio also include Cuvposa, which is indicated for sialorrhea in patients aged 3-18 years with neurologic conditions, such as cerebral; Gliolan, an orally administered drug used for the visualization of various brain tumors; and Treosulfan, a conditioning agent used prior to stem cell transplantation. The company was formerly known as Pediapharm Inc. and changed its name to Medexus Pharmaceuticals Inc. in December 2018. Medexus Pharmaceuticals Inc. is based in Verdun, Canada.

Receive MDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDP Stock News Headlines

September 24, 2022 | americanbankingnews.com
Kenneth D'entremont Purchases 10,000 Shares of Medexus Pharmaceuticals Inc. (CVE:MDP) Stock
September 24, 2022 | americanbankingnews.com
Medexus Pharmaceuticals (CVE:MDP) PT Lowered to C$2.75 at Canaccord Genuity Group
September 23, 2022 | americanbankingnews.com
Medexus Pharmaceuticals (CVE:MDP) Stock Rating Lowered by Raymond James
August 2, 2022 | finance.yahoo.com
Medexus Schedules First Quarter 2023 Conference Call
July 25, 2022 | finance.yahoo.com
Treosulfan NDA Resubmitted to FDA
June 6, 2022 | finance.yahoo.com
Treosulfan Pivotal Study Results Published
May 24, 2022 | finance.yahoo.com
Medexus Pharmaceuticals Provides Update on Resubmission of Treosulfan NDA
March 9, 2022 | finance.yahoo.com
Medexus to Participate in the 34th Annual Roth Conference
March 1, 2022 | finance.yahoo.com
Medexus Pharmaceuticals Announces Deal for Gleolan in the United States
February 22, 2022 | benzinga.com
Raymond James Initiates Coverage On Medexus Pharmaceuticals with Outperform Rating, Announces Price Target of C$5.5
February 15, 2022 | nz.finance.yahoo.com
Medexus Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures
February 14, 2022 | finance.yahoo.com
Medexus Pharmaceuticals Announces Normal Course Issuer Bid, or NCIB, for Convertible Debentures
February 8, 2022 | finance.yahoo.com
Loss-making Medexus Pharmaceuticals (TSE:MDP) has seen earnings and shareholder returns follow the same downward trajectory over past -63%
February 1, 2022 | finance.yahoo.com
Medexus to Present at The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Investor Conference
December 16, 2021 | finance.yahoo.com
Would it Be Fine if You Invest in Medexus Pharmaceuticals (MDP)?
December 2, 2021 | finance.yahoo.com
Medexus to Participate in Two Upcoming Virtual Investor Conferences
November 10, 2021 | ca.finance.yahoo.com
Stocks in play: Medexus Pharmaceuticals Inc.
November 10, 2021 | finance.yahoo.com
Medexus Pharmaceuticals Reports Financial and Operational Results for the Three- and Six-Month Periods Ending September 30, 2021
November 4, 2021 | finance.yahoo.com
Medexus Schedules Second Quarter Fiscal 2022 Conference Call
November 1, 2021 | baystreet.ca
Phama Company Shares Rise Ahead of FDA Review
August 12, 2021 | finance.yahoo.com
Medexus Completes Enrollment in Phase 4 Clinical Trial of IXINITY® Targeting Label Expansion for Pediatric Hemophilia B Patients
August 3, 2021 | finance.yahoo.com
Complete Response Letter Received from FDA for Treosulfan
July 7, 2021 | finance.yahoo.com
MEDEXUS PHARMACEUTICALS INC (MDP.TO) stock forecast and price target
June 10, 2021 | ca.finance.yahoo.com
Medexus Strengthens Medical Affairs Team in Preparation for Planned Treosulfan Launch
June 9, 2021 | ca.finance.yahoo.com
Medexus Announces Availability of Triamcinolone Hexacetonide in the United States
See More Headlines
Receive MDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
CVE:MDP
CUSIP
N/A
CIK
N/A
Web
www.medexus.com
Phone
514-762-2626
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$5.25
High Stock Price Forecast
C$11.00
Low Stock Price Forecast
C$2.00
Forecasted Upside/Downside
-32.3%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
9.23
P/E Growth
-2153
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
1,174.36
Current Ratio
1.19
Quick Ratio
0.74

Sales & Book Value

Annual Sales
C$108.29 million
Price / Sales
1.37
Cash Flow
C$0.62 per share
Price / Cash Flow
12.46
Book Value
C$0.38 per share
Price / Book
20.50

Miscellaneous

Outstanding Shares
19,167,000
Free Float
N/A
Market Cap
C$148.54 million
Optionable
Optionable
Beta
N/A

Key Executives

  • Mr. Kenneth d'Entremont
    CEO & Director
  • Mr. Roland Boivin
    Chief Financial Officer
  • Mr. Bill Poncy
    Sr. VP of Commercial Operations - United States
  • Mr. Brian Peters
    VP of Sales & Marketing - United States
  • Ms. Tina Byers CFA
    Exec. of Investor Relations
  • Mr. Michael Pine
    Sr. VP of Bus. Devel. & Strategy
  • Mr. Michael David Adelman (Age 50)
    Gen. Mang., U.S. Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













MDP Stock - Frequently Asked Questions

Should I buy or sell Medexus Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Medexus Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" MDP shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MDP, but not buy additional shares or sell existing shares.
View MDP analyst ratings or view top-rated stocks.

What is Medexus Pharmaceuticals' stock price forecast for 2022?

1 equities research analysts have issued 1 year target prices for Medexus Pharmaceuticals' stock. Their MDP share price forecasts range from C$2.00 to C$11.00. On average, they expect the company's stock price to reach C$5.25 in the next year. This suggests that the stock has a possible downside of 32.3%.
View analysts price targets for MDP or view top-rated stocks among Wall Street analysts.

How have MDP shares performed in 2022?

Medexus Pharmaceuticals' stock was trading at C$7.75 on January 1st, 2022. Since then, MDP stock has increased by 0.0% and is now trading at C$7.75.
View the best growth stocks for 2022 here.

What other stocks do shareholders of Medexus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medexus Pharmaceuticals investors own include Gatekeeper Systems (GSI), Enghouse Systems (ENGH), Ag Growth International (AFN).

What is Medexus Pharmaceuticals' stock symbol?

Medexus Pharmaceuticals trades on the Canadian Venture Exchange (CVE) under the ticker symbol "MDP."

How do I buy shares of Medexus Pharmaceuticals?

Shares of MDP stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Medexus Pharmaceuticals' stock price today?

One share of MDP stock can currently be purchased for approximately C$7.75.

How much money does Medexus Pharmaceuticals make?

Medexus Pharmaceuticals (CVE:MDP) has a market capitalization of C$148.54 million and generates C$108.29 million in revenue each year.

How can I contact Medexus Pharmaceuticals?

The official website for the company is www.medexus.com. The company can be reached via phone at 514-762-2626.

This page (CVE:MDP) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.